达肺饮联合多索茶碱及沙丁胺醇治疗COPD 39例

Albuterol Aerosol Joined with D oxofylline and Dafei Drink in the Treatment for 39 Cases of COPD

目的:探究达肺饮联合沙丁胺醇及多索茶碱治疗慢性阻塞肺疾病(COPD)的临床疗效。方法:将78例COPD患者随机分为2组,每组39例。对照组使用沙丁胺醇+多索茶碱进行治疗,观察组在对照组治疗基础上加服达肺饮,1剂/d,水煎分服。2组均连续用药30天后,对比2组临床疗效、不良反应及治疗前后用力肺活量(FVC)、气道阻力(Raw)、每分钟最大通气量(MVV)、C反应蛋白(CRP)及肿瘤坏死因子α(TNF-α)水平。结果:总有效率观察组为89.74%(35/39),对照组为71.79%(28/39),2组比较差异有统计学意义(P<0.05)。不良反应发生率观察组为15.38%(6/39),对照组为28.21%(11/39),2组比较差异有统计学意义(P<0.05)。治疗后2组CRP、TNF-α水平显著下降(P<0.05),且观察组下降水平大于对照组(P<0.05)。治疗后2组FVC、MVV均显著升高,Raw显著下降,且观察组均较对照组下降更显著,差异有统计学意义(P<0.05)。结论:达肺饮联合多索茶碱及沙丁胺醇治疗COPD临床疗效较好,能改善患者肺功能,降低患者炎性因子水平,同时具有较高的安全性。

Objective:To explore curative effects of albuterol aerosol,doxofylline and Dafei drink in the treatment for COPD.Methods:All 78 patients were randomized into two groups,39 cases each group.The control group aodpted albuterol aerosol and doxofylline,and the observation group took Dafei drink on the foundation of Western medicine,one dose each day,water decocted.Both groups were treated for 30 days consecutively,to compare clinical effects,adverse reaction,forced vital capacity(FVC),airway resistance(Raw),maximum ventilation volume per minute(MVV),C reactive protein(CRP)and tumor necrosis factor(TNF-α)level between both groups.Results:Total effective rate of the observation group was 89.74%(35/39),higher than 71.79%(28/39)of the control group,and the difference showed statistical meaning(P<0.05).Adverse reaction incidence of the observation group was 15.38%(6/39),lower than 28.21%(11/39)of the control group,and the difference showed statistical meaning(P<0.05).The levels of CRP and TNF-αdropped in both groups after treating(P<0.05),the decrease of the observation group was larger than that of the control group(P<0.05).After treating,FVC and MVV lifted notably in both groups(P<0.05),Raw decreased apparently(P<0.05),and the observation group was more significant than the control group(P<0.05).Conclusion:Albuterol aerosol,doxofylline and Dafei drink are effective in the treatment for COPD,it could improve pulmonary function and reduce inflammatory factor levels with higher safety.